Company news: Suven Life Sciences

| Updated on May 23, 2019 Published on May 23, 2019

Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in central nervous system diseases, on Thursday announced that the last patient has completed the last visit for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. The company expects to report the topline data of this study at the Alzheimer’s Association International Conference on July 17 at Los Angeles. Shares of Suven Life moved up 3.4 per cent at ₹259.10 on the BSE.

Published on May 23, 2019
This article is closed for comments.
Please Email the Editor